Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update-Reference-Cited by-同舟云学术

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update

Published:2020-02-14 Issue:3 Volume:41 Page:
ISSN:1868-1891
Container-title:Hormone Molecular Biology and Clinical Investigation
language:en
Short-container-title:

Author:

Revaux Aurélie¹²,Carbonnel Marie²³,Kanso Frédéric⁴,Naoura Iptissem²³,Asmar Jennifer²³,Kadhel Philippe²³⁵,Ayoubi Jean-Marc²³

Affiliation:

1. Department of Gynecology and Obstetrics , Foch Hospital , 40 Rue Worth , 92150 Suresnes , France

2. Faculté de Médecine Paris Ouest (UVSQ) , Versailles , France

3. Department of Gynecology and Obstetrics , Foch Hospital , Suresnes , France

4. Department of Digestive Surgery , Foch Hospital , Suresnes , France

5. CHU de Pointe-à-Pitre, Univ Antilles, Univ Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) – UMR_S 1085 , Pointe-à-Pitre , France

Abstract

Abstract In the treatment of advanced-stage epithelial ovarian cancer (EOC)-associated surgery and chemotherapy with intravenous platinum/taxane-based therapy most patients had early or late recurrence. Prevention of progression and recurrence is a major objective for the management of EOC. Recently, many clinical studies have evaluated the strategy with hyperthermic intraoperative intraperitoneal (IP) drug delivery. This is an update of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in EOC and a view for future strategies. Until recently studies on HIPEC in patients with EOC were mostly retrospective and heterogeneous. Thanks to recent clinical trials, it is reasonable to conclude that surgical cytoreduction and HIPEC is an interesting approach in the management of EOC without increasing morbidity.

Publisher

Walter de Gruyter GmbH

Subject

Endocrinology,Molecular Biology,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://www.degruyter.com/document/doi/10.1515/hmbci-2019-0028/pdf

Reference53 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

2. Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen L, Copeland L, et al. Ovarian cancer, version 2.2013. J Natl Compr Cancer Netw. 2013;11:1199–209.

3. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19:3–10.

4. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT. High volume intraperitoneal chemotherapy (“belly Bath”) for ovarian cancer. Pharmacologic basis and early results. Cancer Chemother Pharmacol. 1978;1:161–6.

5. Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin – a Sankai Gynecology Study Group (SGSG) Study. Gynecol Oncol. 2005;99:591–6.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perforated Gastric Cancer: A Case Report and Literature Review;Cureus;2024-01-06

2. A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis;Computational and Mathematical Methods in Medicine;2022-05-25

3. Anesthesia and Cancer, Friend or Foe? A Narrative Review;Frontiers in Oncology;2021-12-23

4. Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy;Urology;2021-09

5. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Epithelial Ovarian Cancer: A 20-Year Single-Center Experience;Cancers;2021-01-29